Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Apr 25, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 18, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 15, 2024
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Apr 15, 2024
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Apr 11, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Apr 10, 2024
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Apr 02, 2024
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 28, 2024
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Mar 26, 2024
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Mar 25, 2024
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
1
2
3
4
5
6
<<
<
>
>>
Privacy